For the millions of adults living with HIV who depend on daily medication to maintain viral suppression and near-normal life expectancy, a comprehensive clinical review published in the New England Journal of Medicine arrives as an authoritative synthesis of where antiretroviral science currently stands — and what practitioners and patients should understand about modern treatment architecture.
The review, spanning fourteen pages in NEJM's July 2026 issue, covers the mechanistic landscape of antiretroviral therapy (ART), examining how distinct drug classes — including integrase strand transfer inhibitors, nucleoside reverse transcriptase inhibitors, capsid inhibitors, and long-acting injectable formulations — function at the molecular level to block HIV replication. The piece addresses evolving resistance profiles, the pharmacokinetic advantages of newer agents, and the clinical rationale behind current first-line regimen selection, situating these within both treatment-naïve and treatment-experienced populations. Specific attention appears to be given to long-acting injectable options such as cabotegravir plus rilpivirine, which have shifted adherence paradigms significantly since their approval.
From a broader perspective, this type of landmark review in NEJM carries substantial weight precisely because ART science has undergone rapid transformation in a short period. A decade ago, daily oral polypharmacy was standard; today, bimonthly injectable regimens and investigational twice-yearly subcutaneous options are redefining what therapeutic adherence can look like for people with HIV. The longevity implications are considerable — individuals on effective, well-tolerated ART now achieve life expectancy approaching that of HIV-negative peers, making optimized regimen selection a genuine healthspan question, not merely a virological one. Key limitations of any review article apply here: it synthesizes existing evidence rather than generating new data, and guideline evolution may outpace even a well-researched synthesis. Still, for clinicians and informed patients navigating an increasingly complex pharmacological landscape, this constitutes an essential reference point.